TABLE A-1 Phase 1 Trials of Malaria Vaccines That Did Not (or Have Not Yet) Progressed to Phase 2

Type of Vaccine

Vaccine Details

MIDRP Involvement

Results

References

Preerythrocytic Vaccines

CSP recombinant

VaxSynCSA: full-length

CSP, baculovirus expressed/alum

No

Minimally immunogenic (n = 20)

Herrington et al., 1992

 

CVD 908-rCSP: CSP expressed in attenuated Salmonella

No

Immunogenic to 3/10 participants

Gonzalez et al., 1994

DNA based

CSP-DNA

NMRC

Good cellular but no antibody responses (n = 20)

Le et al., 2000;

Wang et al., 1998

DNA prime/protein boost

PfCSP DNA/RTS,S AS02A boost

NMRC

Antibody, CD4 and CD8 T cells

Epstein et al., 2004

Synthetic peptide

MAP1NYU: PfCSP-repeats/alum/QS21

No

Good antibody responses

Nardin et al., 2000

 

PfCSP-repeats + T-cell epitopes + Pam3Cys polyoxime

No

Good antibody and CD4+ T-cell responses

Nardin et al., 2001

Viruslike particle

ICC-1132: HBcAg + CSP repeats + T-cell epitopes

No

Antibody, CD4+ T cells

Nardin et al., 2004;

Oliveira et al., 2005



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement